Teachers Advisors LLC boosted its position in shares of Endologix, Inc. (NASDAQ:ELGX) by 40.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 198,912 shares of the medical instruments supplier’s stock after purchasing an additional 57,675 shares during the period. Teachers Advisors LLC owned 0.24% of Endologix worth $967,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ELGX. Alliancebernstein L.P. increased its stake in Endologix by 11.5% during the second quarter. Alliancebernstein L.P. now owns 108,757 shares of the medical instruments supplier’s stock valued at $529,000 after acquiring an additional 11,200 shares during the period. Swiss National Bank grew its stake in shares of Endologix by 14.3% in the 2nd quarter. Swiss National Bank now owns 137,900 shares of the medical instruments supplier’s stock valued at $670,000 after purchasing an additional 17,300 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of Endologix by 10.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 321,309 shares of the medical instruments supplier’s stock valued at $1,562,000 after purchasing an additional 30,429 shares during the period. American International Group Inc. grew its stake in shares of Endologix by 7.1% in the 1st quarter. American International Group Inc. now owns 49,906 shares of the medical instruments supplier’s stock valued at $361,000 after purchasing an additional 3,290 shares during the period. Finally, MARSHALL WACE ASIA Ltd bought a new stake in shares of Endologix in the 1st quarter valued at approximately $323,000.
A number of research analysts have recently weighed in on ELGX shares. Canaccord Genuity reissued a “hold” rating and issued a $5.00 price target on shares of Endologix in a research note on Wednesday. Stifel Nicolaus lowered their price objective on shares of Endologix from $6.00 to $5.50 and set a “hold” rating for the company in a research report on Wednesday. Royal Bank Of Canada lowered their price objective on shares of Endologix from $5.00 to $4.00 and set a “sector perform” rating for the company in a research report on Wednesday. ValuEngine cut shares of Endologix from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, BidaskClub cut shares of Endologix from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Two analysts have rated the stock with a sell rating and eleven have assigned a hold rating to the stock. Endologix has a consensus rating of “Hold” and a consensus target price of $6.13.
Shares of Endologix, Inc. (ELGX) opened at $5.06 on Friday. The company has a quick ratio of 2.12, a current ratio of 2.90 and a debt-to-equity ratio of 2.61. Endologix, Inc. has a 1 year low of $4.08 and a 1 year high of $10.36.
TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/12/endologix-inc-elgx-stake-raised-by-teachers-advisors-llc.html.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.